Business Context and Reporting Period
Company: Inhibrx Biosciences, Inc. (INBX)
Filing Type: Form 8-K (Current Report)
Report Date: August 13, 2026
Reporting Period: The filing announces financial results for the three and six months ended June 30, 2026.
Key Financial Metrics
The provided text serves as a cover report referencing a press release (Exhibit 99.1) for detailed data. The filing text itself does not provide specific values for the following metrics:
- Revenue: Not stated in the filing text.
- Profit/Loss: Not stated in the filing text.
- Cash Flow: Not stated in the filing text.
- Margins: Not stated in the filing text.
- Debt and Liquidity: Not stated in the filing text.
Material Changes
The filing text does not contain specific comparative data or descriptions of material changes versus prior periods. Investors must refer to the attached press release (Exhibit 99.1) for this information.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the issuance of a press release regarding Q2 2026 results but does not include the content of that commentary.
Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" under Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for the period ended June 30, 2026.
- Verify the company's cash runway and burn rate, as these are critical for a biotechnology firm not reporting revenue in the summary text.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.
- Confirm if the company has elected to use the extended transition period for new accounting standards (indicated as "Yes" in the filing).